Pfizer weighs sale of consumer healthcare business

(Reuters) - Pfizer said on Tuesday it was considering the sale or spin-off of its consumer healthcare business, shaking up the industry and potentially putting a headache pill to lip balm operation worth as much as $14 billion up for grabs.

Pfizer weighs sale of consumer healthcare business
Read More


Bagikan Berita Ini